Skip to main content

Advertisement

Table 2 Family history of cancer and risk of esophageal and gastric adenocarcinoma

From: Family history of cancer and gastroesophageal disorders and risk of esophageal and gastric adenocarcinomas: a case–control study

History of cancer among first degree relatives   EA GCA DGA
Controls Cases OR (95% CI)a P a Cases OR (95% CI)a P a Cases OR (95% CI)a P a
Any cancer           
 No 668 68 1.00 (ref)   90 1.00 (ref)   160 1.00 (ref)  
 Yes 629 78 1.02 (0.68-1.54) 0.92 91 1.04 (0.71-1.53) 0.83 122 0.83 (0.60-1.15) 0.27
 Late-onset 481 58 0.96 (0.62-1.49) 0.85 63 0.96 (0.63-1.46) 0.84 89 0.81 (0.56-1.16) 0.25
 Early-onset 148 20 1.24 (0.66-2.35) 0.50 28 1.33 (0.74-2.38) 0.34 33 0.90 (0.54-1.48) 0.67
Gastrointestinal cancer           
Any gastrointestinal cancerb           
 No 1101 125 1.00 (ref)   148 1.00 (ref)   226 1.00 (ref)  
 Yes 196 21 0.87 (0.48-1.59) 0.66 33 1.19 (0.71-1.97) 0.51 56 1.45 (0.95-2.23) 0.087
 Late-onset 153 16 0.85 (0.44-1.65) 0.63 26 1.23 (0.70-2.14) 0.47 40 1.31 (0.80-2.16) 0.28
 Early-onset 43 5 0.98 (0.29-3.33) 0.97 7 1.04 (0.36-3.02) 0.95 16 1.84 (0.90-3.78) 0.095
Esophageal cancer           
 No 1290 145 1.00 (ref)   176 1.00 (ref)   280 1.00 (ref)  
 Yes 7 1 - - 5 5.18 (1.23-21.79) 0.025 2 - -
Gastric cancer           
 No 1241 141 1.00 (ref)   171 1.00 (ref)   260 1.00 (ref)  
 Yes 56 5 0.92 (0.32-2.65) 0.87 10 1.57 (0.72-3.45) 0.26 22 2.15 (1.18-3.91) 0.012
Colorectal cancer           
 No 1222 138 1.00 (ref)   171 1.00 (ref)   260 1.00 (ref)  
 Yes 75 8 0.94 (0.39-2.27) 0.89 10 0.70 (0.27-1.79) 0.46 22 1.21 (0.61-2.39) 0.59
Liver cancer           
 No 1267 139 1.00 (ref)   179 1.00 (ref)   276 1.00 (ref)  
 Yes 30 7 1.94 (0.64-5.83) 0.24 2 - - 6 0.51 (0.13-2.01) 0.34
Pancreatic cancer           
 No 1275 145 1.00 (ref)   176 1.00 (ref)   276 1.00 (ref)  
 Yes 22 1 - - 5 1.55 (0.44-5.43) 0.49 6 2.17 (0.72-6.51) 0.17
Non-gastrointestinal cancer           
Lung cancer           
 No 1202 132 1.00 (ref)   164 1.00 (ref)   267 1.00 (ref)  
 Yes 95 14 1.03 (0.48-2.24) 0.93 17 0.92 (0.43-1.98) 0.84 15 1.05 (0.52-2.11) 0.90
Upper respiratory organ cancer           
 No 1172 128 1.00 (ref)   157 1.00 (ref)   260 1.00 (ref)  
 Yes 125 18 0.98 (0.50-1.93) 0.96 24 1.22 (0.67-2.20) 0.51 22 1.02 (0.57-1.85) 0.94
Skin/bone/connective tissue cancer           
 No 1225 141 1.00 (ref)   174 1.00 (ref)   272 1.00 (ref)  
 Yes 72 5 0.61 (0.21-1.74) 0.35 7 0.44 (0.14-1.46) 0.18 10 1.06 (0.40-2.79) 0.90
Lymphatic/hematopoietic cancer           
 No 1256 141 1.00 (ref)   179 1.00 (ref)   272 1.00 (ref)  
 Yes 41 5 1.49 (0.56-3.96) 0.43 2 - - 10 0.90 (0.32-2.55) 0.84
Prostate cancer           
 No 1224 130 1.00 (ref)   170 1.00 (ref)   272 1.00 (ref)  
 Yes 73 16 2.84 (1.50-5.36) 0.001 11 1.45 (0.70-3.01) 0.32 10 0.44 (0.17-1.16) 0.10
Breast cancer           
 No 1168 137 1.00 (ref)   167 1.00 (ref)   258 1.00 (ref)  
 Yes 129 9 0.60 (0.28-1.28) 0.19 14 0.68 (0.33-1.40) 0.30 24 0.78 (0.42-1.45) 0.44
Female reproductive organ cancer           
 No 1228 132 1.00 (ref)   167 1.00 (ref)   263 1.00 (ref)  
 Yes 67 14 1.59 (0.72-3.51) 0.25 13 1.56 (0.74-3.27) 0.24 17 1.02 (0.52-2.02) 0.94
Unknown primary site           
 No 1234 139 1.00 (ref)   176 1.00 (ref)   270 1.00 (ref)  
 Yes 63 7 0.76 (0.29-1.99) 0.58 5 0.54 (0.19-1.54) 0.25 12 0.80 (0.38-1.66) 0.55
  1. Abbreviations: EA, esophageal adenocarcinoma; GCA, gastric cardiac adenocarcinoma; DGA, distal gastric adenocarcinoma; OR, odds ratio; CI, confidence interval.
  2. aResults were estimated from multivariate polytomous logistic regression, with adjustment for age, sex, race, education, birth place, cigarette smoking status, body mass index, history of diabetes, and history of other malignancies. History of cancer among first degree relatives was unknown for 17 participants.
  3. bGastrointestinal cancer includes malignant neoplasm of the gastrointestinal tract, including esophagus, stomach, small intestine, colon, rectum, rectosigmoid junction, anus, liver, gallbladder, intrahepatic and extrahepatic bile ducts, pancreas, and other and ill-defined sites within the digestive organs and peritoneum.